RxDoctor Payments Data

Mark Minaudo, DO

Gastroenterology · Grand Blanc, MINPI 1942239819

Payments from drug & device makers

$3,745in general payments, 2019–2025

Across 122 payments — averaging $30.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Intercept Pharmaceuticals, Inc.$430
  • Gilead$379
  • Johnson & Johnson$216
  • Pfizer$209
  • E.r. Squibb & Sons, L.L.C.$187
  • plus $594 from 8 others

What the payments were for

  • Food & beverage$3,72299%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,745 in reported general payments places this provider in the 55th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$66,576
Medicare patients
327
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$297,240
Humira PenAdalimumab12$89,584
XifaxanRifaximin27$77,422
Mesalamine16$11,322
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg198$5,537
Ursodiol21$4,339
Omeprazole154$3,022
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates41$2,797
Colestipol Hcl13$1,999
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl58$1,166
Pantoprazole Sodium43$1,120
Ondansetron OdtOndansetron14$803
Lactulose12$641
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl30$606
Spironolactone18$333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$216$297,24012 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$53$77,42227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Grand Blanc

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →